← Becton Dickinson and overview

Becton Dickinson and vs Sansure Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Becton Dickinson and Company (BDX)

Q3 2026
▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

  • Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.

    This is the core financial result that directly moved BDX shares and confirms business momentum.

  • GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.

    It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.

  • Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.

    It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.

  • $19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.

    It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.

September 2026
▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

  • Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.

    This is the core financial result that directly moved BDX shares and confirms business momentum.

  • GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.

    It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.

  • Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.

    It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.

  • $19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.

    It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.

Latest
▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

  • Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.

    This is the core financial result that directly moved BDX shares and confirms business momentum.

  • GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.

    It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.

  • Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.

    It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.

  • $19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.

    It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.

Sansure Biotech Inc (688289.CG)

Q3 2026
▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

  • First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.

    This is the biggest new negative force on the stock and explains the core earnings deterioration.

  • Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.

    Negative cash flow is a new financial red flag that adds to the profit decline.

  • New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.

    These approvals are the main positive pipeline news that could offset weak current earnings over time.

  • Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.

    This captures both the positive capital return and the negative overhang from forced share sales.

August 2026
▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

  • First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.

    This is the biggest new negative force on the stock and explains the core earnings deterioration.

  • Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.

    Negative cash flow is a new financial red flag that adds to the profit decline.

  • New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.

    These approvals are the main positive pipeline news that could offset weak current earnings over time.

  • Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.

    This captures both the positive capital return and the negative overhang from forced share sales.

Latest
▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

  • First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.

    This is the biggest new negative force on the stock and explains the core earnings deterioration.

  • Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.

    Negative cash flow is a new financial red flag that adds to the profit decline.

  • New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.

    These approvals are the main positive pipeline news that could offset weak current earnings over time.

  • Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.

    This captures both the positive capital return and the negative overhang from forced share sales.